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Thiabendazole, was first discovered to be an
unusually potent broad spectrum anthelmintic
(1, 2, 3, 4, 5). Extensive acute and chronic toxicity
studies in a variety of animal species have shown
thiabendazole to be well tolerated even when ad-
ministered orally over a 2-year period (6). More
recently thiabendazole was discovered to sup-
press the growth of saprophytic fungi (7). The
present paper deals with the effect of thiabenda-
zole in vitro on various pathogenic and saprophy-
tic fungi. Included in the latter group of or-
ganisms are cultures which are known to produce
mycotoxins. Comparative studies were made
with nystatin and griseofulvin.
MATERIALS AND METHODS
Thiabendazole is a white, crystalline com-
pound which has the following structural formula:
cçt
The compound is only slightly soluble in water;
its solubility is a function of pH, being more sol-
uble in dilute acids and alkali than at neutral pH.
Its maximum solubility with hydrochloric acid is
at pH 2.5 where it will give a 1.5 per cent solution.
It is a stable compound both as a solid and in solu-
tion and will form colored complexes with metals
such as iron. Stock solutions of thiabendazole
hydrochloride were prepared in sterile water
whereas the relatively insoluble agents nystatin
(Mycostatin sterile powder) and griseofulvin were
homogenized to fine suspensions in 1 per cent
Emulphor EL 720. The stock solutions or suspen-
sions were freshly prepared at concentrations ten-
fold those employed in the test medium. In the
present investigation the concentrations of ny-
statin are expressed as "Mycostatin." One mg of
the powder was equivalent to approximately 3000
units.
The fungistatic activity of thiabendazole
against the saprophytic fungi was determined by
the streak method on agar plates. Drug concen-
trations ranging from 0.1 to 100 g per nil in Sab-
euraud's Dextrose Agar (Difco) were employed.
Penicillin and streptomycin at concentrations of
20 and 40 g per nil respectively, were added to the
medium to control possible bacterial contamina-
tion. Control plates, with and without emulphor,
were also run to evaluate the effect of the vehicle
on fungal growth. The inocula were prepared by
growing the cultures in Sabouraud's Dextrose
liquid medium at 24° C and a fine suspension pre-
pared by hand grinding the cultures in sterile glass
homogenizers. The resulting fungal suspensions
were streaked on the surface of the agar with a
standard wire loop. The plates were incubated at
34° C and inspected daily for evidence of growth.
The terminal readings for the majority of the
cultures were made after 4 days incubation. The
lowest level of drug which prevented growth was
recorded as the minimal inhibitory concentration.
The comparative fungistatic and fungicidal ac-
tivity of thiabendazole against the pathogenic
strains was evaluated by a tube dilution pro-
cedure using Sabouraud's Dextrose medium con-
taining 10 per cent heat-inactivated horse serum.
The preparation of the inocula was similar to that
described above for the saprophytic fungi. The
final fungal suspensions were such that 0.1 nil im-
parted a slight turbidity to the test medium.
Following inoculation, the tubes were incubated
at 37° C and growth was recorded at intervals over
a 20-day period. Since the various fungi did not
grow at the same rate, the final readings for each
culture were made when heavy growth was evident
in the non-medicated tubes. The minimal inhibi-
tory concentration in the medicated tubes was
considered to be the lowest drug level which pre-
vented growth. The fungicidal effect of the drugs
was evaluated by subculturing 0.05 to 0.1 ml from
each of a series of drug tubes bracketing the in-
hibitory concentration in the fungistatic tests.
Subcultures were made to Sabouraud Dextrose
Agar slants. The foregoing inocula contained
visible mycelium or yeast-like sediment. The
presence or absence of growth was recorded after
8 to 21 days incubation at 37° C.
RESULTS
Fungistatic activity against saprophytic fungi:
The results of in vitro experiments on the fungi-
static activity of thiabendazole against a series
of saprophytic fungi are presented in Table 1.
Thiabendazole was found to be a potent anti-
mycotic agent ag&nst a number of the genera
employed. Several strains of alternaria, aspergil-
lus, chaetomicum and penicillium were inhibited
by concentrations of thiabendazole ranging from
1 to 20 pg per ml. Many of these particular
strains are known to produce mycotoxins and
some strains have been implicated in ocular in-
fections. Comparative values of the relative ac-
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TABLE 1
Fungistatic act1vity of thiabendazole, griseofulvin and nystatin (Mycostatin) aga1n8t saprophytic fungi
(agar streak-dilution method)
Culture Culture No.
Minimal Inhibitory Concentration (pg/mi)
Thiabendazole Griseofulvin yc5fin)
Acremonium potronii MF2861 >100 >100 >100
Alternaria solani MF3845 4 >100 4
Aspergillus flavus CII 4 >100 5
Aspergillus fumigatus MF483 8 >100 8
Aspergillus luchensis 220 20 — >100
Aspergillus nidulans MF122 8 >100 100
Aspergillus niger — 40 — >100
Aspergillus glaucus MF345 1 >100 4
Aspergillus terreus MF183 4 >100 >100
Chaetomicum clivaceum MF2886 20 >100 4
Curvularia lunata MF3922 >100 >100 4
Fusarium oxysporum MF3293 >100 >100 >100
Fusarium reticulatum MF3288 >100 >100 >100
Hypomyces inomoese MF2919 >100 >100 >100
Monilia nigra MF3084 10 >50 >50
Mucor mucedo MF2055 >100 >100 80
Paecilomyces varioti MF3741 >100 >100 >100
Penicillium oxalicum MF914 1 >100 4
Penicilliurn spinulosum MF1002 1 >100 4
Penicillium funiculosum QM475 <1 — >100
Rhizopus oryzae MF2048 >100 >100 >100
Scopulariopsis koningi MF3770 >100 >100 >100
tivity of thiabendazole and nystatin against
fungi susceptible to both agents revealed thia-
bendazole to compare favorably with nystatin.
At the drug concentrations employed, griseoful-
yin was inactive in vitro against all of the strains
employed.
Fungistatic and fungicidal activity of thia-
bendazole and nystatin (Mycostatin) against
pathogenic fungi: Since the results of the fungi-
static and fungicidal tests were essentially identi-
cal, in the interest of conserving space only the
results of the fungicidal tests are presented in
(Table 2).
Thiabendazole was particularly active against
the dermatophytes, microsporum and trichophy-
ton and against the strain of Hormodendrum
pedrosoi. Fungistatic and fungicidal activity
against these microorganisms was observed with
concentrations in the range of from 0.5 to 6 ig
per ml. Thiabendazole was somewhat superior to
nystatin. The strains of Cryptococcus neoformans
were also killed by thiabendazole, although rather
high concentrations were required to destroy this
organism. Moderately high concentrations of
thiabeiidazole were required to demonstrate
fungistatic and fungicidal activity against
Nocardia bra8iliensis, Rhodotorula rubra and
Sporotrichum schenckii. At the maximum concen-
trations tested, thiabendazole was inactive
against eight strains of candida.
Fungistatic and fungicidal activity of thia-
bendazole against griseofulvin-sensitive dermato-
phytes: Since thiabendazole was effective against
dermatophytes, its activity was evaluated in
comparison to that of griseofulvin against a num-
ber of strains of trichophyton and microsporum.
Here again, the results of the fungistatic and
fungicidal tests were essentially identical and
therefore in the interest of space only the results
of the fungicidal tests are presented in Table 3.
Thiabendazole was found to be highly active
against these dermatophytes, and in most in-
stances, it was more active than griseofi.ilvin.
Fungistatic activity of serum from thiabenda-
zole-treated dogs: Serum taken from dogs 1
hours following an oral dose of 200 mg per kg
thiabendazole inhibited the growth of Trichophy-
ton mentagrophytes. Similarly, plasma samples
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TABLE 2
Fun gicidal activity of thiabendazole and nystatin (Mycostatin) against pathogenic fungi
(Sabouraud dextrose agar)
Culture Culture No.
Minimal Inhibitory Concentration (g1'm1)
Thiabendazole (My'ostatin)
Cryptococcus neoformans Flam 30—40 50-60
Cryptococcus neoformans P90-2 20—30 60—70
Geotrichum sp Petri 15 60
Hansenula anomala NRRL-Y-552 >1000 125—250
Hormodendrum pedrosoi 10221 10—15 >500
Microsporum audouini Cruz <7.8 <0.1
Microsporum audouini Beatto <7.8 <7.8
Microsporum gypseum NYM 0.5—1.0 8—10
Nocardia brai1iensis C >1000 >1000
Scopulariopsis sp >1000 250—500
Sporotrichum schenckii 9523 >1000 250—500
Trichophyton mentagrophytes 10270 1—2 10—15
Trichophyton gypseum NYM 6—8 <15
Trichophyton rubrum NYSC <1 8-10
Trichophyton rubrum Woodella <1 <8
Candida albicans 1537 >1000 >50
* Concentration expressed as Mycostatin per ml.
TABLE 3
Fun gicidal activity of thiabendazole against griseo-
fulvin-sensitive pathogenic fungi (Sabouraud
dextrose agar)
Culture
Fwigicidal concen-
tration (g/ml)
Thiaben- Griseo-
dazole fulvin
Trichophyton gypseum (NYM).
Trichophyton mentagrophytes
(10270)
Trichophyton rubrum (NYSC).
Trichophyton rubrum
(Woodella)
Microsporum audouini (Cruz)..
Microsporum gypseum (NYM).
8
2
<1
<1
1.3
1
10
6
10
10
1.3
4
from dogs infused intravenously with a dose of
40 mg/kg of thiabendazole over a 36 minute
period gave rise to thiabendazole concentrations
as high as 30 jg/m1. Tenfold dilutions of this
serum were fungicidal for T. mentagrophytes.
DISCtJSSION
It is apparent from the data obtained in this
study that thiabendazole is a potent, rather
broad spectrum, antimycotic agent in vitro.
Microgram amounts of the compound inhibit the
growth of a vañety of saprophytic and patho-
genic fungi. The compound appears to be highly
effective against saprophytic organisms includ-
ing cultures which produce mycotoxins. It is also
highly active against the pathogenic dermato-
phytes and particularly against the genera micro-
sporum and trichophyton. Equally important
are the observations that thiabendazole is
fungicidal as well as fungistatic. It is noteworthy
that serum has no apparent effect on the efficacy
of the compound. These findings suggest, among
other things, that thiabendazole may prove to be
a useful topical agent for the treatment of super-
ficial fungus infections due to the microsporum
and tñchophyton. In addition to its high anti-
fungal potency, thiabendazole is a colorless,
stable non-irritating compound which can be ap-
plied to mucous membranes in high concentra-
tions. In view of these properties, thiabendazole
may also prove of interest in the topical treat-
ment of ocular infections due to fungi.
It is obvious from the data reported here and
from other reports describing its low toxicity (6)
that thiabendazole should be investigated in vivo
to determine its value as a therapeutic agent for
the treatment of several superficial and deep
mycotic infections. It is noteworthy that thia—
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bendazole is higMy active against Trichophyton
rubrum an organism which gives rise to fungus
infections of the soles and palms and which does
not readily respond to griseofulvin. Similarly,
thiabendazole has a high order of activity against
Hormodertdrum pedrosoi, an organism which
resists all forms of current treatment. In consider-
ing the potential of thiabendazole as an antifungal
agent in vivo, it is important t4 note that thia-
bendazole is well tolerated by a variety of animal
species even when administered daily over a 2-
year period. At times, moderate doses of thia-
bendazole may induce emesis, but this appears to
be a central effect and one which can be sup-
pressed by chiorpromazine or related drugs and
which may subside if thiabendazole therapy is
continued (3, 6). Some of the drug is rapidly
absorbed following oral administration and as
noted in the present paper, plasma levels may be
obtained which will inhibit the growth of fungi.
On the other hand, thiabendazole is rather rapidly
metabolized and is converted to several metabolic
products which are not as active against fungi
as the parent compound. In view of these findings,
it is difficult at this time to predict the potential
value of thiabendazole as a systemic agent for
the treatment of fungus infections. It is obvious
that in order to be effective, the drug must reach
the site of the infecting microorganism and re-
main there for a sufficient length of time to ad-
versely affect the fungi. This will vary with the
nature and site of the infection and the specific
organism giving rise to the disease. Available
data indicate that orally administered thiabenda-
zole is absorbed by human subjects. However, at
present we have little information regarding the
concentration and distribution of thiabendazole
in the skin and other tissues of man. Moreover,
essentially nothing is known about the plasma
levels or toxicity following parenteral adminis-
tration in man. Studies are in progress to obtain
such information and to determine the action of
thiabendazole against fungi not included in the
present report.
Finally, the data obtained in this study lead
one to believe that thiabendazole may be useful
as an antifungal agent to control fungus growth
in feeds and other perishable materials. Its broad
antimycotic and anthelmintic spectrum, com-
bined with stability, lack of taste and color, and
a low order of toxicity are among its many at-
tributes.
SUMMARY
Thiabendazole is a known potent anthelmintic
which, in the present report, has been demon-
strated to be higMy active in vitro against a
variety of saprophytic and pathogenic fungi. It is
particularly active against strains of trichophyton
and microsporum and it also inhibits the growth
of cultures producing mycotoxins. Serum does
not affect the antifungal activity of thiabenda-
zole. Moderate amounts of the drug are absorbed
following oral administration and serum from
dogs treated perorally or intravenously with
thiabendazole inhibits the growth of pathogenic
fungi in vitro. Thiabendazole is unusually well
tolerated by a variety of animal species even
when given daily over a 2-year period. The pres-
ent report suggests that thiabendazole should
prove to be a valuable agent to control the growth
of fungi.
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